A New Chapter in IT Services: Lenovo PCCW Solutions Starts First Day of Operation as a New Company
14.9.2022 15:50:00 EEST | Business Wire | Press release
Today marks the first day of operation for Lenovo PCCW Solutions Limited1, the new strategic partnership between Lenovo Group (HKSE: 992) (ADR: LNVGY) and PCCW (HKSE: 0008) set to capitalize on the estimated US$320 billion Asia IT services market.
The new company provides one-stop customer solutions that integrate IT services, devices, and digital infrastructure, and empowers clients to transform their businesses and operations with technology – from managing complex integrations to enhancing competitiveness with innovative applications.
Through the partnership, the company benefits from Lenovo’s global footprint in more than 180 markets, broad portfolio of end-to-end solutions, solid pedigree in innovation, and strong go-to-market and delivery capabilities.
Ken Wong, Executive Vice President of Lenovo and President of Lenovo Solutions and Services Group, said, “The partnership marks an important milestone in Lenovo’s service-led transformation journey since the formation of our Solutions and Services Group, as it bolsters the company’s capabilities to drive leadership in IT solutions. The synergy of capabilities and talents across the two organizations will help the new company grow in reach and competitiveness in markets across the Asia Pacific region.”
PCCW Solutions has been ranked number one in Systems Integration and Custom Application Development in Hong Kong SAR by IDC for eight consecutive years since 20142. The new company builds upon PCCW Solutions’ track record as one of the region’s leading IT services providers. The 4,000-strong IT professionals will continue to partner closely with our customers to help them succeed in a more complex and rapidly evolving technology landscape.
Jerry Li, CEO of Lenovo PCCW Solutions, said, “This strategic partnership is a unique opportunity to accelerate the growth of our IT solutions business in the region. The new company, Lenovo PCCW Solutions, enables our customers to call upon a diverse wealth of skills, expertise, and go-to-market capabilities across Lenovo Solutions and Services Group. We are excited to embark on this growth journey, which enables us to expand our skillset, footprint, and solutions portfolio. With the combined strengths of our highly skilled talent, we look forward to contributing further to smart city development in the region.”
Market data estimates the Asia IT services market to be worth approximately US$320 billion in 2022, with expected growth at a CAGR of more than 10% to exceed US$470 billion by 2026. Lenovo PCCW Solutions is uniquely positioned to capture the growth opportunities in the market.
About Lenovo PCCW Solutions Limited
Lenovo PCCW Solutions is a leading technology solutions powerhouse in Asia Pacific. A strategic partnership formed between Lenovo and PCCW in August 2022, the company offers market-leading solutions to help organizations transform their operations, increase competitiveness, and enhance innovation through technology. Its wide range of technology solutions and service offerings include system integration, application development and operation, IT outsourcing, managed services, digital solutions, and technical services. To find out more about Lenovo PCCW Solutions, please visit www.pccwsolutions.com.
1 The company was previously referred to as “PCCW Lenovo Technology Solutions” in the 14 June 2022 filing with Hong Kong Stock Exchange. https://news.lenovo.com/pressroom/press-releases/lenovo-and-pccw-partnership/
2 https://www.pccwsolutions.com/site/en/news-entry/20220518/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005363/en/
Contact information
Rhoda Wong
Zeno Group
Tel: +65 9637 1462
Email: rhoda.wong@zenogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom